Brought to you by 
Jazz enters oncology space through $650mm purchase of EUSA Pharma
01 Dec 2020
Executive Summary
Jazz Pharmaceuticals PLC (women’s health and neurology) will pay $650mm up front, plus up to $50mm in sales-based earn-outs, to acquire EUSA Pharma Inc., a private specialty pharmaceuticals company that develops and sells therapies for cancer and cancer supportive care.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Implantable Devices
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Jazz enters oncology space through $650mm purchase of EUSA Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice